文献速递湿疹皮炎与荨麻疹

Amlitelimab治疗特应性皮炎IIa期随机对照试验

Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial.
PubMed 文献 · Br J Dermatol · 2023-01-01

该IIa期双盲安慰剂对照试验在成人中重度特应性皮炎患者中评估Amlitelimab的安全性和疗效,共随机分配89例患者至低剂量静脉Amlitelimab 200mg、高剂量500mg或安慰剂组,主要终点为治疗出现的不良事件发生率和第16周EASI较基线变化百分比。结果显示Amlitelimab总体耐受良好,低剂量组EASI较基线变化百分比为-80.12%(95%CI -95.55至-64.68;P=0.009 vs 安慰剂),高剂量组为-69.97%(95%CI -85.04至-54.60;P=0.07 vs 安慰剂),安慰剂组为-49.37%(95%CI -66.02至-32.72)。

要点

  • Amlitelimab总体耐受良好,未报告超敏反应事件。
  • 低剂量组第16周EASI较基线变化百分比为-80.12%,与安慰剂差异有统计学意义。
  • 高剂量组第16周EASI较基线变化百分比为-69.97%,与安慰剂差异无统计学意义。

核心结论

  • 靶向表达OX40L的抗原呈递细胞的新方法Amlitelimab耐受良好,并在特应性皮炎中产生有临床意义的改善。

研究设计与样本

  • IIa期双盲安慰剂对照研究,在德国、波兰、西班牙和英国的19家医院进行。
  • 符合条件的成人中重度特应性皮炎患者按1:1:1随机分配至低剂量静脉Amlitelimab 200mg、高剂量静脉Amlitelimab 500mg或安慰剂组,随后在第4、8、12周接受三次维持剂量(负荷剂量的50%),安全性随访至第36周。
  • 共随机分配89例患者至低剂量组(n=29)、高剂量组(n=30)或安慰剂组(n=29),其中88例接受治疗[女性37例(42%),男性51例(58%);平均(SD)年龄33.6(11.9)岁]。
  • 共同主要终点为治疗出现的不良事件发生率(所有接受至少1剂研究药物的患者)和第16周EASI平均变化百分比(全分析集)。

主要发现

  • Amlitelimab总体耐受良好,安全性特征无异常;未报告超敏反应事件。
  • 第16周EASI较基线最小二乘均值变化百分比:低剂量组(n=27)为-80.12%(95%CI -95.55至-64.68;P=0.009 vs 安慰剂),高剂量组(n=27)为-69.97%(95%CI -85.04至-54.60;P=0.07 vs 安慰剂),安慰剂组(n=24)为-49.37%(95%CI -66.02至-32.72)。
  • 从第2周至第16周,Amlitelimab组EASI降低数值上大于安慰剂组。

关键数值与推荐

  • 共同主要终点:治疗出现的不良事件发生率(所有接受至少1剂研究药物的患者)和第16周EASI平均变化百分比(全分析集)。
  • 第16周EASI较基线变化百分比:低剂量组-80.12%(95%CI -95.55至-64.68;P=0.009 vs 安慰剂),高剂量组-69.97%(95%CI -85.04至-54.60;P=0.07 vs 安慰剂),安慰剂组-49.37%(95%CI -66.02至-32.72)。

临床怎么用

  • Amlitelimab总体耐受良好,并在成人中重度特应性皮炎中产生有临床意义的改善。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis (AD) is an inflammatory skin disease with significant unmet need. Blockade of the OX40-OX40 ligand (OX40L) costimulation pathway by targeting OX40L on antigen-presenting cells (APCs) with a fully human noncytotoxic, nondepleting anti-OX40L monoclonal antibody (amlitelimab; SAR445229; KY1005) is a novel way to modulate persistent inflammation. OBJECTIVES: To assess the safety and efficacy of amlitelimab over 16 weeks in adults with AD in a phase IIa double-blind placebo-controlled study. METHODS: The study was conducted at 19 hospitals in Germany, Poland, Spain and the UK. Eligible patients with moderate-to-severe AD were randomized (1 : 1 : 1) to low-dose intravenous (IV) amlitelimab (200 mg), high-dose IV amlitelimab (500 mg) or placebo, followed by three maintenance doses (50% of loading dose) at 4, 8 and 12 weeks, with safety follow-up to week 36. The co-primary endpoints were the incidence of treatment-emergent adverse events (all patients who received ≥ 1 dose of the study drug) and mean percentage change in Eczema Area and Severity Index (EASI) to week 16 (full analysis set). RESULTS: Between 13 December 2018 and 12 May 2020, 89 patients were randomly assigned to low- (n = 29) or high-dose amlitelimab (n = 30) or placebo (n = 29), of whom 88 proceeded to treatment [37 women (42%), 51 (58%) men; mean (SD) age 33.6 (11.9) years]. Amlitelimab was generally well tolerated with an unremarkable safety profile; no hypersensitivity events were reported. For the primary endpoint, the least square mean percentage change in EASI from baseline to week 16 was -80.12% [95% confidence interval (CI) -95.55 to -64.68; P = 0.009 vs. placebo] and -69.97% (95% CI -85.04 to -54.60; P = 0.07 vs. placebo) for the low- (n = 27) and high-dose (n = 27) amlitelimab groups, respectively, vs. -49.37% (95% CI -66.02 to -32.72) for placebo (n = 24). Numerically greater reductions in EASI were observed for amlitelimab vs. placebo from weeks 2 to 16. CONCLUSIONS: Novel targeting of OX40L-expressing APCs with amlitelimab was well tolerated and resulted in clinically meaningful improvements in AD.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Weidinger S, Bieber T, Cork MJ, et al. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial. Br J Dermatol. 2023. PMID: 37463508. doi:10.1093/bjd/ljad240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。